Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trastuzumab biosimilar - Zhejiang Hisun Pharmaceutical

Next Previous
Drug Profile

Trastuzumab biosimilar - Zhejiang Hisun Pharmaceutical

Alternative Names: Anruize; HS-022

Latest Information Update: 10 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zhejiang Hisun Pharmaceutical
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Gastric cancer; HER2 positive breast cancer

Most Recent Events

  • 13 Sep 2023 Launched for Gastric cancer in China (IV) prior to September 2023 (IV) (BioRay Pharmaceutical pipeline, September 2023)
  • 13 Sep 2023 Launched for HER2-positive-breast-cancer in China prior to September 2023 (IV) (BioRay Pharmaceutical pipeline, September 2023)
  • 30 Nov 2019 Zhejiang Hisun Pharmaceutical completes enrolment in its phase III trial for HER2-positive-breast-cancer(Second-line therapy or greater) in China (IV, Infusion), prior to November 2019 (ChiCTR1900027196)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top